Average Co-Inventor Count = 6.35
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Sanofi (31 from 1,456 patents)
2. Antaros Medical Ab (1 from 2 patents)
32 patents:
1. 11141489 - Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
2. 11046743 - Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
3. 10806797 - Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
4. 10792367 - Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
5. 10758592 - Exendin-4 derivatives as dual GLP1/glucagon agonists
6. 10583174 - FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
7. 10538567 - Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
8. 10519211 - Compounds as peptidic GLP1/glucagon/GIP receptor agonists
9. 10253079 - Functionalized Exendin-4 derivatives
10. 9982029 - Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
11. 9932381 - Exendin-4 derivatives as selective glucagon receptor agonists
12. 9834527 - Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
13. 9789165 - Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
14. 9775904 - Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
15. 9771406 - Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4